J 2016

Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients

POLANSKÁ, Hana, Martina RAUDENSKÁ, Kristýna HUDCOVÁ, Jaromír GUMULEC, Markéta SVOBODOVÁ et. al.

Basic information

Original name

Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients

Authors

POLANSKÁ, Hana (203 Czech Republic, belonging to the institution), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Kristýna HUDCOVÁ (203 Czech Republic, belonging to the institution), Jaromír GUMULEC (203 Czech Republic, belonging to the institution), Markéta SVOBODOVÁ (203 Czech Republic, belonging to the institution), Zbynek HEGER (203 Czech Republic), Michaela FOJTŮ (203 Czech Republic, belonging to the institution), Hana BINKOVÁ (203 Czech Republic), Zuzana HORÁKOVÁ (203 Czech Republic), Rom KOSTŘICA (203 Czech Republic), Vojtech ADAM (203 Czech Republic), Rene KIZEK (203 Czech Republic) and Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution)

Edition

Oncology letters, Athens, Spandidos Publications, 2016, 1792-1074

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.390

RIV identification code

RIV/00216224:14110/16:00088233

Organization unit

Faculty of Medicine

UT WoS

000382211900085

Keywords in English

spinocellular cancer; biomarker; EGFR; head and neck tumors; plasma; diagnosis

Tags

Tags

International impact, Reviewed
Změněno: 26/4/2017 12:07, Soňa Böhmová

Abstract

V originále

Approximately 90% of all head and neck tumors are squamous cell carcinomas. The overall survival of patients with head and neck squamous cell carcinoma (HNSCC) is low (<= 50%). A non-invasive marker of disease progression is sorely required. The present study focused on the plasmatic levels of epidermal growth factor receptor (EGFR) in HNSCC patients (N=92) compared with healthy (N=29) and diabetic [type 2 diabetes mellitus (T2DM); N=26] controls. Enzyme-linked immunosorbent assay using antibodies against the extracellular region of EGFR (L25-S645) was performed. No significant changes were observed between diabetic and healthy controls. However, there were significantly higher EGFR plasma levels in HNSCC patients compared with both control groups (P=0.001 and 0.005, respectively). Receiver operating characteristic curve analysis identified a sensitivity of 76.09%, a specificity of 67.27% and an area under curve of 0.727 for this comparison. No significant association was observed between EGFR plasma levels and tumor stage, tumor grade, lymph node or distant metastasis occurrence, smoking habit or hypertension. However, the presence of human papillomavirus infection and T2DM in HNSCC patients had borderline effect on the plasma EGFR levels. Survival analysis revealed no significant influence of plasmatic EGFR levels on the overall and disease-specific survival of HNSCC patients. In conclusion, EGFR plasma levels appear to be a relatively promising diagnostic, but poor prognostic, HNSCC marker.

Links

GA16-12454S, research and development project
Name: Charakterizace a modifikace komplexní odpovědi buněk nádorů hlavy a krku na různá záření - krok kupředu ke kombinované personalizované (radio)terapii
Investor: Czech Science Foundation
MUNI/A/1365/2015, interní kód MU
Name: Kardiovaskulární systém: od modelu přes terapii k prevenci (Acronym: KAMOTEPRE)
Investor: Masaryk University, Category A
MUNI/A/1426/2015, interní kód MU
Name: Genetická a epigenetická patofyziologie vybraných stavů (Acronym: Genetika a epigenetika)
Investor: Masaryk University, Category A
NT14337, research and development project
Name: Studium a charakterizace primárních nádorových buněčných linií spinocelulárních karcinomů v oblasti hlavy a krku a jejich maligní potenciál.
Investor: Ministry of Health of the CR